AU2012350482B2 - Imidazolidinedione compounds and their uses - Google Patents

Imidazolidinedione compounds and their uses Download PDF

Info

Publication number
AU2012350482B2
AU2012350482B2 AU2012350482A AU2012350482A AU2012350482B2 AU 2012350482 B2 AU2012350482 B2 AU 2012350482B2 AU 2012350482 A AU2012350482 A AU 2012350482A AU 2012350482 A AU2012350482 A AU 2012350482A AU 2012350482 B2 AU2012350482 B2 AU 2012350482B2
Authority
AU
Australia
Prior art keywords
compound
deuterated
mmol
methyl
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012350482A
Other languages
English (en)
Other versions
AU2012350482A1 (en
Inventor
Yuanwei Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hinova Pharmaceuticals Inc
Original Assignee
Hinova Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hinova Pharmaceuticals Inc filed Critical Hinova Pharmaceuticals Inc
Publication of AU2012350482A1 publication Critical patent/AU2012350482A1/en
Application granted granted Critical
Publication of AU2012350482B2 publication Critical patent/AU2012350482B2/en
Assigned to HINOVA PHARMACEUTICAL INC. reassignment HINOVA PHARMACEUTICAL INC. Request to Amend Deed and Register Assignors: HC PHARMACEUTICAL CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012350482A 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses Active AU2012350482B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CN201110418859.0 2011-12-14
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Publications (2)

Publication Number Publication Date
AU2012350482A1 AU2012350482A1 (en) 2014-07-10
AU2012350482B2 true AU2012350482B2 (en) 2017-02-16

Family

ID=48583248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012350482A Active AU2012350482B2 (en) 2011-12-14 2012-12-13 Imidazolidinedione compounds and their uses

Country Status (9)

Country Link
US (1) US9346764B2 (enExample)
EP (1) EP2792674B1 (enExample)
JP (1) JP5933746B2 (enExample)
CN (2) CN103159680A (enExample)
AU (1) AU2012350482B2 (enExample)
CA (1) CA2859224C (enExample)
ES (1) ES2587903T3 (enExample)
PL (1) PL2792674T3 (enExample)
WO (1) WO2013087004A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014190895A1 (zh) * 2013-05-29 2014-12-04 成都海创药业有限公司 咪唑二酮类化合物及其用途
RU2016110546A (ru) * 2013-09-19 2017-10-24 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированная лекарственная терапия
CN105188699B (zh) * 2013-10-14 2017-04-26 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
KR102125661B1 (ko) 2017-02-13 2020-06-22 강푸 바이오파마슈티칼즈 리미티드 전립선암 치료용 조합, 약학 조성물 및 치료 방법
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
JP2021519322A (ja) * 2018-03-29 2021-08-10 ヒノバ ファーマシューティカルズ インコーポレイテッド 重水素化イミダゾリジンジオン化合物とその用途
US11753392B2 (en) 2018-04-13 2023-09-12 Hinova Pharmaceuticals Inc. Method for synthesis of deuterated amide and deuterated sulfonamide
AU2019268481B2 (en) * 2018-05-14 2025-04-03 Hinova Pharmaceuticals Inc. HC-1119 formulation, preparation method and use thereof
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
CN112442009B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
WO2021185291A1 (zh) * 2020-03-17 2021-09-23 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
BR112023002295A2 (pt) 2020-08-13 2023-03-14 Pfizer Terapia de combinação
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608436C (en) * 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) * 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
KR101456994B1 (ko) 2009-09-10 2014-11-04 통유지 안드로겐 수용체 길항제 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Also Published As

Publication number Publication date
WO2013087004A1 (zh) 2013-06-20
JP5933746B2 (ja) 2016-06-15
AU2012350482A1 (en) 2014-07-10
EP2792674B1 (en) 2016-05-25
PL2792674T3 (pl) 2016-12-30
CN104024228A (zh) 2014-09-03
HK1198166A1 (en) 2015-03-13
CA2859224A1 (en) 2013-06-20
CA2859224C (en) 2019-03-19
US20140371284A1 (en) 2014-12-18
CN103159680A (zh) 2013-06-19
CN104024228B (zh) 2015-07-08
EP2792674A1 (en) 2014-10-22
US9346764B2 (en) 2016-05-24
JP2015501820A (ja) 2015-01-19
EP2792674A4 (en) 2015-06-17
ES2587903T3 (es) 2016-10-27

Similar Documents

Publication Publication Date Title
EP2792674B1 (en) Imidazolidinedione compounds and their uses
AU2014273618B2 (en) Imidazole diketone compound and use thereof
JP5718372B2 (ja) ジアリールチオヒダントイン化合物およびジアリールヒダントイン化合物を合成するためのプロセス
US20120184580A1 (en) Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
EP3480199B1 (en) Imidazopyridinamine phenyl derivative and use thereof
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
CN105646389A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
TW201016671A (en) Novel imidazolidine compounds as androgen receptor modulators
EP2485804A1 (en) Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
WO2023208174A1 (zh) 去泛素化酶抑制剂及其应用
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
CN110963957B (zh) N-芳香酰胺类化合物及其制备方法和用途
KR20260054707A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용
HK1198166B (en) Imidazolidinedione compounds and their uses
KR102406248B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
CN117126134A (zh) 新型四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN120112529A (zh) 一种含吡啶的化合物及其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: HINOVA PHARMACEUTICAL INC.

Free format text: FORMER NAME(S): HC PHARMACEUTICAL CO., LTD.